Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 6/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.53 |
| ▸ | COQ8A | Q8NI60 | 4/20 | 0.53 |
| ▸ | NLK | Q9UBE8 | 4/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929965 | 0.83 | CCNB2 (0.50) | EGFRGAKRIPK2COQ8ANLK | |
| SCHEMBL4925395 | 0.80 | CCNB2 (0.54) | IGF1REGFRGAKRIPK2COQ8A | |
| SCHEMBL4917317 | 0.79 | GAK (0.53) | EGFRGAKRIPK2COQ8ANLK | |
| SCHEMBL14115561 | 0.77 | CCNB2 (0.54) | EGFRGAKRIPK2COQ8ANLK | |
| SCHEMBL3895212 | 0.77 | EGFR (0.63) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL2446373 | 0.77 | GAK (0.55) | EGFRGAKRIPK2COQ8ANLK | |
| SCHEMBL14155006 | 0.76 | CCNB2 (0.47) | EGFRGAKRIPK2COQ8ANLK | |
| SCHEMBL4929127 | 0.75 | PTK6 (0.49) | EGFRINSRKDRTEKGAK | |
| SCHEMBL2446494 | 0.73 | CCNB2 (0.48) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL4718175 | 0.72 | FYN (0.48) | CCNB2CDK1CCNB1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-1874769-B1 | NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | IGF1R, IGFBP1, ERBB2 | IGF1R 1/4885EGFR 13/4885INSR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.